bendamustine hydrochloride has been researched along with Cancer of Spleen in 4 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (25.00) | 29.6817 |
| 2010's | 3 (75.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Bergamaschini, L; Castelli, R; Deliliers, GL | 1 |
| Bonaldi, L; Martines, A; Nabergoj, M; Piazza, F; Pizzi, M; Scapinello, G; Semenzato, G; Trentin, L; Vio, S; Visentin, A | 1 |
| Carter, JB; Cohen, JM; Ferry, JA; Nazarian, RM; Takvorian, RW | 1 |
| Frickhofen, N; Hackenberg, U; Josten, KM; Jung, B; Kirchmaier, CM; Manner, H; Plum, N; Tonassi, L | 1 |
1 review(s) available for bendamustine hydrochloride and Cancer of Spleen
| Article | Year |
|---|---|
Rare presentation of secondary cutaneous involvement by splenic marginal zone lymphoma: report of a case and review of the literature.
Topics: Aged; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; Bendamustine Hydrochloride; Biomarkers, Tumor; Biopsy; Female; Humans; Immunohistochemistry; Lymphoma, B-Cell, Marginal Zone; Nitrogen Mustard Compounds; Predictive Value of Tests; Remission Induction; Rituximab; Skin Neoplasms; Splenic Neoplasms; Time Factors; Treatment Outcome | 2015 |
3 other study(ies) available for bendamustine hydrochloride and Cancer of Spleen
| Article | Year |
|---|---|
First-line treatment with bendamustine and rituximab, in patients with intermediate-/high-risk splenic marginal zone lymphomas.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bendamustine Hydrochloride; Female; Follow-Up Studies; Humans; Lymphoma, B-Cell, Marginal Zone; Male; Prognosis; Rituximab; Splenic Neoplasms | 2017 |
Splenic marginal zone lymphoma with a de novo t(8;14)(q24;q32) and a prolymphocytoid evolution responsive to rituximab-bendamustine.
Topics: Abnormal Karyotype; Antineoplastic Combined Chemotherapy Protocols; Bendamustine Hydrochloride; Cell Lineage; Chromosomes, Human, Pair 12; Chromosomes, Human, Pair 14; Chromosomes, Human, Pair 8; Disease Progression; Female; Genes, Immunoglobulin; Genes, myc; Humans; Immunoglobulin Heavy Chains; Lymphocytes; Lymphoma, B-Cell, Marginal Zone; Middle Aged; Remission Induction; Rituximab; Splenic Neoplasms; Translocation, Genetic; Trisomy | 2018 |
Successful treatment of catastrophic antiphospholipid antibody syndrome (CAPS) associated with splenic marginal-zone lymphoma with low-molecular weight heparin, rituximab and bendamustine.
Topics: Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Anticoagulants; Antineoplastic Agents; Antiphospholipid Syndrome; Bendamustine Hydrochloride; Female; Heparin, Low-Molecular-Weight; Humans; Lymphoma, B-Cell; Nitrogen Mustard Compounds; Rituximab; Splenic Neoplasms | 2008 |